Edge Therapeutics, Inc. (EDGE) At $10.66 Forms Top; Checkpoint Therapeutics (CKPT) Shorts Raised By 100%

Checkpoint Therapeutics Incorporated (NASDAQ:CKPT) had an increase of 100% in short interest. CKPT’s SI was 400 shares in January as released by FINRA. Its up 100% from 200 shares previously. The stock decreased 2.30% or $0.09 during the last trading session, reaching $3.82. About 37,018 shares traded. Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) has 0.00% since January 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Edge Therapeutics, Inc. (EDGE) formed multiple top with $11.51 target or 8.00% above today’s $10.66 share price. Edge Therapeutics, Inc. (EDGE) has $328.96 million valuation. The stock increased 3.00% or $0.31 during the last trading session, reaching $10.66. About 134,332 shares traded or 78.56% up from the average. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 23.72% since January 18, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company has market cap of $97.44 million. The Company’s pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. It currently has negative earnings. The firm is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase.

Analysts await Edge Therapeutics, Inc. (NASDAQ:EDGE) to report earnings on March, 1. They expect $-0.47 earnings per share, down 42.42% or $0.14 from last year’s $-0.33 per share. After $-0.37 actual earnings per share reported by Edge Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 27.03% negative EPS growth.

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics has $34 highest and $18 lowest target. $27.25’s average target is 155.63% above currents $10.66 stock price. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. The company was initiated on Monday, October 26 by Credit Suisse. The firm has “Buy” rating by Guggenheim given on Monday, October 26. The firm earned “Market Outperform” rating on Monday, October 26 by JMP Securities. Credit Suisse maintained Edge Therapeutics, Inc. (NASDAQ:EDGE) rating on Monday, May 9. Credit Suisse has “Outperform” rating and $18 target. Leerink Swann initiated the shares of EDGE in report on Monday, October 26 with “Outperform” rating.